Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Obrindatamab |
Trade Name | |
Synonyms | MGD009|MGD-009|MGD 009 |
Drug Descriptions |
Obrindatamab (MGD009) is an activating bispecific molecule that binds to both B7-H3 (CD276) and CD3, therefore bringing the targeted B7-H3-expressing cells together with T-cells, resulting in cytotoxic immune response (J Clin Oncol., 34 (no. 15_suppl): abstract TPS3105). |
DrugClasses | CD276 Antibody 16 CD3 Antibody 99 |
CAS Registry Number | 2069959-72-2 |
NCIT ID | C136983 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Obrindatamab | Obrindatamab | 0 | 1 |
Obrindatamab + Retifanlimab | Obrindatamab Retifanlimab | 0 | 1 |